DEPLOYDatabase

Robot model

Toumai

MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory…

Track Toumai
Manufacturer
MicroPort MedBot
Form factor
surgical
Maturity
research
Lifecycle
active

The verified answer

As of Aug 2026, DEPLOY verifies Toumai, a surgical by MicroPort MedBot (research). 2 sources back the record.

Regulatory status1 NMPA registration1 FDA 510(k) clearance

Toumai holds 1 NMPA registration and 1 FDA 510(k) clearance, per the DEPLOY registry.

See all 2 filings

Overview

MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory clearance, granted in January 2022. The system uses 3D HD vision and wristed surgical instruments for minimally invasive procedures across urology, gynecology, and general surgery.

A single-port variant, the Toumai SP, received separate NMPA clearance in March 2025, and a tele-operative version received NMPA approval in May 2025 as the first tele-surgical robot authorized for commercial clinical use globally.

Verified vs. claimed

Maturity stage
research(Lab-stage only; no commercial or public deployment reported.)
Sources on file
View all sources →

No verified deployments on file. DEPLOY tracks independently-sourced deployment evidence separately from manufacturer capability claims.

Key facts

Form factor

surgical

Arms

4

Procedure types

3

Regulatory clearance

NMPA clearance granted in January 2022

Tele-surgical approval

NMPA approval in May 2025 as first tele-surgical robot authorized for commercial clinical use globally

Specs

Arms

4

Visualization

3D HD vision

Clearance body

NMPA

Procedure types

3

Data & sources

Web sources

2

2 sources backing this record.View all →

Pricing

No verified price is on record for Toumai. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

Toumai on the deployment map

View the global map

Where Toumai is verified operating. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Regulatory filings (2)

Safety record

No incidents on record for Toumai.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (2)

  1. MicroPort Toumai Surgical Robot Receives NMPA Approval | MicroPort MedBot · https://www.medbotsurgical.com/en/news/53.html
  2. Toumai Laparoscopic Surgical Robot | MicroPort · https://microport.com/news/microport-toumai-surgical-robot-receives-nmpa-approval-becoming-the-first-commercialized-four-arm-laparoscopic-surgical-robot-developed-in-china

Common questions

What is Toumai?
MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory clearance, granted in January 2022. The system uses 3D HD vision and wristed surgical instruments for minimally invasive procedures across urology, gynecology, and general surgery. A single-port variant, the Toumai SP, received separate NMPA clearance in March 2025, and a tele-operative version received NMPA approval in May 2025 as the first tele-surgical robot authorized for commercial clinical use globally.
How much does Toumai cost?
Toumai's price is not publicly disclosed. DEPLOY has no verified price on record for Toumai from MicroPort MedBot. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is Toumai actually deployed in the real world?
Toumai is at the research stage: it exists, but DEPLOY has no verified real-world deployment on record. Manufacturer capability claims should be read as claims pending independent verification.
Who makes Toumai?
Toumai is made by MicroPort MedBot, based in Shanghai, China, founded in 2015.
Can you buy Toumai?
Toumai is at research stage and is not yet available for sale.
Is Toumai FDA cleared?
Toumai has 2 regulatory records on the DEPLOY registry: NMPA registration, granted; FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.
What are alternatives to Toumai?
On the DEPLOY registry, comparable surgical robots to Toumai include Edison Histotripsy System, da Vinci (and Ion), Toumai, Stryker Mako SmartRobotics.
How does Toumai compare to Edison Histotripsy System?
Toumai and Edison Histotripsy System (HistoSonics · 14 deployments) are both surgical robots on the DEPLOY registry. Toumai has 0 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is Toumai a top surgical?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Toumai ranks in roughly the top 11% of surgical models tracked by the registry.
What is Toumai's maturity stage?
Toumai is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.
Where is Toumai deployed?
No verified deployments of Toumai are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
Is Toumai safe?
Toumai has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
How does Toumai compare to da Vinci?
Toumai and da Vinci achieve comparable safety profiles, surgical outcomes, and postoperative results, according to peer-reviewed studies. The da Vinci system has shorter docking and console times. Toumai's key advantage is remote surgery capability, including the world's first registered clinical trial for a tele-surgical robot across cross-regional, long-distance, multi-center operations. da Vinci remains the market leader with a larger installed base.
ScienceDirect: Comparison of da Vinci and Toumai Da Vinci vs Toumai comparison
Methodology: Verified · 2 sources (no primary) · last reviewed 2026-07-12

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-07-12

Maturity + lifecycle

Maturity stage: research

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

2
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Toumai.

Recent coverage

Toumai in third-party press

Milestones for China’s medical AI as robot wins EU nod and model tops benchmark - South China Morning Post

Jun 24, 2026

MicroPort MedBot Wins Landmark EU CE Mark for Toumai Remote Surgical Robot - The Globe and Mail

Jun 22, 2026

Brazilian president calls China-developed surgical robot ‘incredible’; device set world record for longest-distance remote surgery in March, company rep tells GT - Global Times

May 21, 2026